2010

On July 15,2010, HealthTronics, Inc. becomes an affiliate of Endo Pharmaceuticals.

On November 4, 2010, Penwest Pharmaceuticals becomes a wholly owned subsidiary of Endo Pharmaceuticals.

On December 1, 2010, Qualitest Pharmaceuticals becomes a wholly owned subsidiary of Endo Pharmaceuticals.

On December 29, 2010, the U.S. Food and Drug Administration approved FORTESTA® Gel.

2009

On March 23, 2009, Endo Pharmaceuticals successfully completed its acquisition of Indevus Pharmaceuticals, Inc. Indevus brought us multiple marketed products that enhance revenue growth, a specialized infrastructure focused in urology, endocrinology and oncology, and a strong drug-development pipeline.

Endo relaunches VALSTAR^®.

2008

Endo entered into a licensing agreement with Novartis to obtain the exclusive U.S. marketing rights for the prescription medicine Voltaren^® Gel (diclofenac sodium topical gel) 1%. Voltaren Gel received regulatory approval in October 2007 from the U.S. Food and Drug Administration.

David Holveck is named President, Chief Executive Officer and a Director of Endo. A new executive team is created to take Endo to the next level.

2007

Roger Kimmel appointed chairman of the Board; Carol Ammon retired.

Endo entered into a license and development agreement with Alexza Pharmaceuticals, Inc. for the exclusive clinical development and commercialization rights in North America for Alexza's AZ-003/ EN3294. Currently in Phase I, clinical development, AZ-003 is a hand-held drug device system that uses Alexza's proprietary Staccato^® system inhalation technology to deliver fentanyl.

2006

Endo received FDA approval for OPANA^® and OPANA^® ER, which represented the first internally developed NDAs to be granted FDA approval.

Endo Pharmaceuticals acquires RxKinetix Inc. through an acquisition. The acquisition broadens Endo pipeline with supportive care oncology products, including EN3285, a topical oral-rinse for the prevention of oral mucositis.

2005

Endo Pharmaceuticals acquired exclusive licenses from DURECT Corporation to develop and commercialize a seven-day transdermal sufentanil patch (EN3270).

2004

Endo entered into an agreement with Vernalis for the exclusive rights to market FROVA^® in North America. Launched in the U.S. in June 2002.

2003

Endo further expands its internal sales force by converting the contract pharma sales force, district managers and regional directors to full-time Endo employees.

2002

Endo established its first internal sales force when it converted the contract specialty sales force and district managers into full-time employees to concentrate sales efforts.

Endo reached $1 billion dollars in cumulative sales.

2001

Endo receives FDA approval for PERCOCET^® strengths (7.5/325 and 10/325 oxycodone/acetaminophen).

2000

Endo Pharmaceuticals acquired Algos Pharmaceutical Corporation through a merger. As a result of this merger, Endo Pharmaceuticals became a publicly traded company, under the NASDAQ symbol ENDP.

1999

Endo launched three strengths of its leading brand-name drug PERCOCET^®. After receiving FDA approval, Endo launched LIDODERM^® as its first proprietary, patented product.

1998

Endo licensed LIDODERM® from Hind Healthcare.

1997

Three executives of DuPont Merck acquired certain products from DuPont Merck in a management buyout for $277 million with financing from Kelso & Company, a private equity investment firm purchased all of Endo Laboratories L.L.C.'s generic products along with 12 important brand products, including PERCOCET^® and PERCODAN^®.

Intravenous Products of America, Inc. changed its name to Endo Products

The history of Endo can be traced back to 1920 to a family-run pharmaceutical company originally called Intravenous Products of America, Inc. In 1935 Intravenous Products of America, Inc. changed its name to Endo Products.

In 1950, PERCODAN^® was launched.

In 1970, E.I. du Pont de Nemours and Company (DuPont) acquired Endo. In 1971, PERCOCET^® was launched.

In 1994, DuPont Merck reestablished Endo as a separate entity within the company. This entity was named Endo Laboratories L.L.C. and served as DuPont Merck's generic division.